PET/SPECT/CT Camera for Small Animal Imaging at UMMS

UMMS 用于小动物成像的 PET/SPECT/CT 相机

基本信息

项目摘要

DESCRIPTION (provided by applicant): Interest in small animal imaging has grown in recent years in step with developments in molecular medicine and, in particular, with the emergence of molecular imaging. Modalities such as positron emission tomography (PET) and single photon emission tomography (SPECT) are of considerable value to researchers concerned with external noninvasive imaging of molecular events in vivo. The much higher sensitivities of both SPECT and PET make possible in vivo imaging of tracers at physiological concentrations not possible at present with any other technology especially in deep tissues. While small animal imaging with PET has certainly proven its worth, SPECT offers many advantages including the ability to perform dual labeling studies, the potential for higher intrinsic resolution, 99mTc, the most useful radionuclide in diagnostic nuclear medicine, and iodine radioisotopes (125I and 123I) critical for emerging in vivo proteomics research. NIH-funded investigators and others supporting this application have need for radioactivity measurements in small animals. In some cases, these measurements will benefit from, if not require, the tomographic imaging capability or the higher resolution of a small animal PET/SPECT camera. In all cases, superior spatial and temporal biodistributions will be obtained with the sacrifice of fewer animals. That a single animal can act as its own control is a major advantage, for example in tumor and infection/inflammation studies in which the imaging target tissue is difficult to standardize. The co-registration of radioactivity distribution with anatomy by X-ray computed tomography (CT) is an invaluable asset not yet available commercially in all but one small animal PET camera. In summary, the advantage of PET and SPECT for non-invasive in vivo animal imaging is the vastly higher sensitivity for the detection of biological tracers especially in deep tissues. The preferred method of performing animal biodistributions is animal imaging and the preferred method of animal imaging is on a dedicated small animal camera with matching spatial resolution. We wish to purchase the GammaMedica PET/SPECT/CT camera, the only commercially available small animal camera capable of both PET and SPECT, and equipped with CT capability for anatomical registration and quantitation. This application describes an administration plan with a chain of command from a full-time PhD scientist reporting to a faculty member administrator, both of whom will report to the P.I. who, in turn, will report to an advisory committee. Questions of camera usage and methods of encouraging imaging at UMMS will be considered by the advisory committee of users and non-users that includes members with experience in animal care, administration, conflict resolution and small animal imaging. The P. I. and his collaborators wish to use the High-End Instrumentation Grant as a vehicle to establish the nucleus of a core facility at UMMS for small animal imaging. We believe that this application addresses the goals of the NIH in offering the RFA and the goals of UMMS to expand use on our campus of small animal imaging.
描述(由申请人提供):近年来,随着分子医学的发展,尤其是分子成像的出现,对小动物成像的兴趣已经增长。诸如正电子发射断层扫描(PET)和单光子发射断层扫描(SPECT)之类的模态对于与体内分子事件外部无创成像有关的研究人员具有相当大的价值。 SPECT和PET的敏感性更高,使示踪剂的体内成像成为可能,目前在任何其他技术中都无法使用生理浓度,尤其是在深层组织中。尽管使用PET的小动物成像已经证明了其价值,但SPECT具有许多优势,包括进行双重标记研究的能力,具有较高内在分辨率的潜力,99MTC,99MTC,是诊断核医学中最有用的放射性核素,以及碘放射性病(125i和123i)(125i和123i)(125i和123i)对于新兴的Inviv Invivo Invivo Invivo蛋白质组学研究至关重要。 NIH资助的研究人员和支持此应用的其他人需要在小动物中进行放射性测量。在某些情况下,这些测量值将受益于(如果不需要),则可以从层析成像能力或小型动物宠物/SPECT摄像机的更高分辨率中受益。在所有情况下,牺牲较少的动物都将获得上空和时间生物分布。单个动物可以作为自身的控制是一个主要优点,例如在肿瘤和感染/炎症研究中,成像靶组织很难标准化。通过X射线计算机断层扫描(CT)与解剖结构的放射性分布共同注册是一项宝贵的资产,但在一台小型动物宠物摄像机之外尚未商业上可用。总而言之,对非侵入性体内动物成像的PET和SPECT的优势是检测生物示踪剂特别是在深层组织中的敏感性。执行动物生物分布的首选方法是动物成像,而动物成像的首选方法是在具有匹配空间分辨率的专用小动物相机上。我们希望购买Gammamedica PET/SPECT/CT摄像机,这是唯一能够使用PET和SPECT的商业小型动物相机,并配备了CT功能来进行解剖学注册和定量。该申请描述了一项行政计划,该计划与全日制博士学位科学家的指挥链向教职员工报告,他们俩都将向P.I报告。后来又将向咨询委员会报告。用户和非用户咨询委员会将考虑相机使用和鼓励成像的方法,其中包括具有动物护理,管理,冲突,解决冲突和小动物成像经验的成员。 P. I.及其合作者希望将高端仪器赠款用作建立小动物成像核心设施的核心的工具。我们认为,此应用程序可以解决NIH提供RFA的目标以及在小型动物成像校园内扩大使用的UMMS的目标。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Comparison of 18F PET and 99mTc SPECT imaging in phantoms and in tumored mice.
  • DOI:
    10.1021/bc1001467
  • 发表时间:
    2010-08-18
  • 期刊:
  • 影响因子:
    4.7
  • 作者:
    Cheng, Dengfeng;Wang, Yi;Liu, Xinrong;Pretorius, P. Hendrik;Liang, Minmin;Rusckowski, Mary;Hnatowich, Donald J.
  • 通讯作者:
    Hnatowich, Donald J.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DONALD J HNATOWICH其他文献

DONALD J HNATOWICH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DONALD J HNATOWICH', 18)}}的其他基金

Optical Antisense Breast Tumor Targeting
光学反义乳腺肿瘤靶向
  • 批准号:
    7293968
  • 财政年份:
    2007
  • 资助金额:
    $ 87万
  • 项目类别:
Optical Antisense Breast Tumor Targeting
光学反义乳腺肿瘤靶向
  • 批准号:
    7456519
  • 财政年份:
    2007
  • 资助金额:
    $ 87万
  • 项目类别:
Imaging Survivin mRNA for Cancer Detection
生存素 mRNA 成像用于癌症检测
  • 批准号:
    6731349
  • 财政年份:
    2004
  • 资助金额:
    $ 87万
  • 项目类别:
Imaging Survivin mRNA for Cancer Detection
生存素 mRNA 成像用于癌症检测
  • 批准号:
    6887708
  • 财政年份:
    2004
  • 资助金额:
    $ 87万
  • 项目类别:
Improved Tumor Radiotherapy by MORF pretargeting
通过 MORF 预靶向改进肿瘤放射治疗
  • 批准号:
    6698513
  • 财政年份:
    2002
  • 资助金额:
    $ 87万
  • 项目类别:
Improved Tumor Rediotherapy by MORF Pretargeting
通过 MORF 预靶向改进肿瘤放射治疗
  • 批准号:
    7555377
  • 财政年份:
    2002
  • 资助金额:
    $ 87万
  • 项目类别:
Improved Tumor Rediotherapy by MORF Pretargeting
通过 MORF 预靶向改进肿瘤放射治疗
  • 批准号:
    7258505
  • 财政年份:
    2002
  • 资助金额:
    $ 87万
  • 项目类别:
Improved Tumor Radiotherapy by MORF pretargeting
通过 MORF 预靶向改进肿瘤放射治疗
  • 批准号:
    6622876
  • 财政年份:
    2002
  • 资助金额:
    $ 87万
  • 项目类别:
Improved Tumor Radiotherapy by MORF Pretargeting
通过 MORF 预靶向改进肿瘤放射治疗
  • 批准号:
    7754656
  • 财政年份:
    2002
  • 资助金额:
    $ 87万
  • 项目类别:
Improved Tumor Radiotherapy by MORF pretargeting
通过 MORF 预靶向改进肿瘤放射治疗
  • 批准号:
    6845715
  • 财政年份:
    2002
  • 资助金额:
    $ 87万
  • 项目类别:

相似海外基金

Understanding the relationship between nurse staffing and outcomes: impact of individual nurse education, expertise, and effort level on individual patient outcomes
了解护士人员配置与结果之间的关系:护士个体教育、专业知识和努力水平对个体患者结果的影响
  • 批准号:
    10642570
  • 财政年份:
    2023
  • 资助金额:
    $ 87万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10749843
  • 财政年份:
    2023
  • 资助金额:
    $ 87万
  • 项目类别:
Bioengineering Research and Interdisciplinary Training – ESTEEMED (BRITE)
生物工程研究和跨学科培训 – EST​​EEMED (BRITE)
  • 批准号:
    10653560
  • 财政年份:
    2023
  • 资助金额:
    $ 87万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10729384
  • 财政年份:
    2023
  • 资助金额:
    $ 87万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10942896
  • 财政年份:
    2023
  • 资助金额:
    $ 87万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了